FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
AUSTIN, Texas, April 26, 2022 /PRNewswire/ — Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct […]
Seattle Doctor Sued for Marketing Unproven Stem Cell Treatments
A concerned Washingtonian reported US Stemology’s claims to the Attorney General’s Office that it could treat and prevent COVID-19. Apparently the company made these claims for at least three months in the early stages of the pandemic. The Attorney General’s Office sent a cease and desist letter to US Stemology which made them remove the […]